Difficulty: Medium
Average Score: 69%
Practice
Which of the following benzodiazepines is less likely to cause cumulative and residual effects with multiple doses?
Correct answer
C
Rationale
In the context of safety pharmacology across the lifespan, understanding the pharmacokinetics and pharmacodynamics of benzodiazepines is crucial for safe medication administration. In this scenario, the correct answer is C) Lorazepam.
Lorazepam has a shorter half-life compared to other benzodiazepines listed, which makes it less likely to cause cumulative and residual effects with multiple doses. Its shorter duration of action reduces the risk of drug accumulation in the body, making it a safer choice for individuals who may require repeated dosing.
Analyzing the other options:
A) Clorazepate: Clorazepate has active metabolites that can accumulate and lead to prolonged sedation and effects with repeated doses.
B) Quazepam: Quazepam is a long-acting benzodiazepine, increasing the likelihood of cumulative effects with multiple doses.
D) Prazepam: Prazepam has a long half-life and active metabolites, which can result in cumulative effects and prolonged sedation upon repeated dosing.
Educationally, this question highlights the importance of selecting benzodiazepines with appropriate pharmacokinetic profiles to minimize the risk of cumulative and residual effects in patients. Understanding these differences can help healthcare professionals make informed decisions when prescribing medications, especially in vulnerable populations where drug accumulation can have serious consequences.
Lorazepam has a shorter half-life compared to other benzodiazepines listed, which makes it less likely to cause cumulative and residual effects with multiple doses. Its shorter duration of action reduces the risk of drug accumulation in the body, making it a safer choice for individuals who may require repeated dosing.
Analyzing the other options:
A) Clorazepate: Clorazepate has active metabolites that can accumulate and lead to prolonged sedation and effects with repeated doses.
B) Quazepam: Quazepam is a long-acting benzodiazepine, increasing the likelihood of cumulative effects with multiple doses.
D) Prazepam: Prazepam has a long half-life and active metabolites, which can result in cumulative effects and prolonged sedation upon repeated dosing.
Educationally, this question highlights the importance of selecting benzodiazepines with appropriate pharmacokinetic profiles to minimize the risk of cumulative and residual effects in patients. Understanding these differences can help healthcare professionals make informed decisions when prescribing medications, especially in vulnerable populations where drug accumulation can have serious consequences.